Hansoh Pharmaceutical Group First Half 2024 Earnings: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Simply Wall St · 09/29 01:40

Hansoh Pharmaceutical Group (HKG:3692) First Half 2024 Results

Key Financial Results

  • Revenue: CN¥6.51b (up 44% from 1H 2023).
  • Net income: CN¥2.73b (up 112% from 1H 2023).
  • Profit margin: 42% (up from 29% in 1H 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.46 (up from CN¥0.22 in 1H 2023).
earnings-and-revenue-growth
SEHK:3692 Earnings and Revenue Growth September 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hansoh Pharmaceutical Group Earnings Insights

Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 6.4% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Hansoh Pharmaceutical Group's balance sheet.